Donanemab vs SHR-1707

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Alzheimer's Disease

Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline

Donanemab · Kisunla

Marketed by Eli Lilly

Approved in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT05108922 · Phase 3 · completed

Participants were randomized to donanemab or active-control aducanumab, but the trial was open-label rather than blinded. Both prespecified primary amyloid-clearance comparisons favored donanemab with statistically significant results; the biomarker-based primary endpoint and lack of blinding support a moderate evidence grade rather than a strong one.

Next expected readout: November 2027 · NCT05026866 (registry estimate)

Reported efficacy

Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months); Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 PET Scan in the Low/Medium (Intermediate) Subpopulation (Superiority) on Donanemab Versus Aducanumab (6 Months): Percentage of Participants Who Reach Complete Amyloid Plaque Clearance on Florbetapir F18 Positron Emission Tomography (PET) Scan (Superiority) on Donanemab Versus Aducanumab (6 Months): Donanemab 37.9% (95% CI 26.2 to 49.6) vs Aducanumab 1.6% (95% CI 0 to 4.6) (met)

Result source: NCT05108922

SHR-1707

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Alzheimer's Diseasemonoclonal antibody
Partial signal

NCT05681819 · Phase 1 · completed

The trial randomized 33 participants to SHR-1707 or placebo with triple-blinding, a design able to isolate a genuine drug effect, but its primary outcomes were safety measures rather than a cognitive or functional efficacy endpoint, and results have not yet been posted, so no effect on Alzheimer's disease could be established from this record.

No aligned efficacy figure on record for this race.

Results for Alzheimer's Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDonanemabSHR-1707
CDR-SB, change1.2 vs 1.6−0.4 vs placebowk 76 · n 93NCT03367403—Not reported
ADAS-Cog11, change—Trial running · NCT06996730—Not reported
ADCS-ADL, change—Trial running · NCT06996730—Not reported
MMSE, change-2.4 vs -3.0+0.6 vs placebowk 76 · n 91NCT03367403—Not reported
Amyloid PET, change (centiloids)-84.2 vs -72.2vs Aducanumabwk 78 · n 67NCT05108922
8 other results
  • -86.6 vs -72.2 wk 78 · n 26 · Phase 3 · secondary NCT05108922
  • -80.0 vs -56.1 wk 52 · n 67 · Phase 3 · secondary NCT05108922
  • -84.5 vs -57.8 wk 52 · n 26 · Phase 3 · secondary NCT05108922
  • -62.1 vs -16.4 wk 26 · n 66 · Phase 3 · secondary NCT05108922
  • -64.1 vs -23.8 wk 26 · n 26 · Phase 3 · secondary NCT05108922
  • -64.0 vs -56.1 n 67 · Phase 3 · secondary NCT05108922
  • -64.0 vs -56.1 n 67 · Phase 3 · secondary NCT05108922
  • -64.3 vs -72.2 n 67 · Phase 3 · secondary NCT05108922
—Not reported

CDR-SB, change

Donanemab
1.2 vs 1.6−0.4 vs placebowk 76 · n 93NCT03367403
SHR-1707
—Not reported

ADAS-Cog11, change

Donanemab
—Trial running · NCT06996730
SHR-1707
—Not reported

ADCS-ADL, change

Donanemab
—Trial running · NCT06996730
SHR-1707
—Not reported

MMSE, change

Donanemab
-2.4 vs -3.0+0.6 vs placebowk 76 · n 91NCT03367403
SHR-1707
—Not reported

Amyloid PET, change (centiloids)

Donanemab
-84.2 vs -72.2vs Aducanumabwk 78 · n 67NCT05108922
8 other results
  • -86.6 vs -72.2 wk 78 · n 26 · Phase 3 · secondary NCT05108922
  • -80.0 vs -56.1 wk 52 · n 67 · Phase 3 · secondary NCT05108922
  • -84.5 vs -57.8 wk 52 · n 26 · Phase 3 · secondary NCT05108922
  • -62.1 vs -16.4 wk 26 · n 66 · Phase 3 · secondary NCT05108922
  • -64.1 vs -23.8 wk 26 · n 26 · Phase 3 · secondary NCT05108922
  • -64.0 vs -56.1 n 67 · Phase 3 · secondary NCT05108922
  • -64.0 vs -56.1 n 67 · Phase 3 · secondary NCT05108922
  • -64.3 vs -72.2 n 67 · Phase 3 · secondary NCT05108922
SHR-1707
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1707: no structured comparison results are available for Alzheimer's Disease.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Donanemab: 4 of 4 rows · SHR-1707: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricDonanemab
Dropout rate
21.6%a
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 17 more results
—Part B: Donanemab
NCT04640077 · Phase 2 · registry result, not featured evidence
—Period 2: Part B: Donanemab
NCT04640077 · Phase 2 · registry result, not featured evidence
28.2%Donanemab Monotherapy (Donanemab-M
NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy
20%Donanemab in Combination With LY32
NCT03367403 · Phase 2 · registry result, not featured evidence · combination
0%40 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
14.3%20 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
60%20 mg/kg Q4W
NCT02624778 · Phase 1 · registry result, not featured evidence
—10 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
10%10 mg/kg Q2W
NCT02624778 · Phase 1 · registry result, not featured evidence
50%10 mg/kg Q4W
NCT02624778 · Phase 1 · registry result, not featured evidence
16.7%10 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
18.2%3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%3 mg/kg SC
NCT01837641 · Phase 1 · registry result, not featured evidence
11.1%1 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%1 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%0.3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%0.1 mg/kg / 0.3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
4.1%a
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 17 more results
—Part B: Donanemab
NCT04640077 · Phase 2 · registry result, not featured evidence
—Period 2: Part B: Donanemab
NCT04640077 · Phase 2 · registry result, not featured evidence
15.3%Donanemab Monotherapy (Donanemab-M
NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy
13.3%Donanemab in Combination With LY32
NCT03367403 · Phase 2 · registry result, not featured evidence · combination
0%40 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
0%20 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
20%20 mg/kg Q4W
NCT02624778 · Phase 1 · registry result, not featured evidence
—10 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
0%10 mg/kg Q2W
NCT02624778 · Phase 1 · registry result, not featured evidence
0%10 mg/kg Q4W
NCT02624778 · Phase 1 · registry result, not featured evidence
0%10 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
9.1%3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%3 mg/kg SC
NCT01837641 · Phase 1 · registry result, not featured evidence
0%1 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%1 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%0.3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%0.1 mg/kg / 0.3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
Serious AEs
18.3%a
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 17 more results
—Part B: Donanemab
NCT04640077 · Phase 2 · registry result, not featured evidence
29.1%Period 2: Part B: Donanemab
NCT04640077 · Phase 2 · registry result, not featured evidence
19.8%Donanemab Monotherapy (Donanemab-M
NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy
20%Donanemab in Combination With LY32
NCT03367403 · Phase 2 · registry result, not featured evidence · combination
0%40 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
0%20 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
20%20 mg/kg Q4W
NCT02624778 · Phase 1 · registry result, not featured evidence
0%10 mg/kg SD
NCT02624778 · Phase 1 · registry result, not featured evidence
0%10 mg/kg Q2W
NCT02624778 · Phase 1 · registry result, not featured evidence
12.5%10 mg/kg Q4W
NCT02624778 · Phase 1 · registry result, not featured evidence
0%10 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%3 mg/kg SC
NCT01837641 · Phase 1 · registry result, not featured evidence
11.1%1 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%1 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
28.6%0.3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
0%0.1 mg/kg / 0.3 mg/kg IV
NCT01837641 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
covid-19 28.2%
amyloid related imaging abnormality-oedema/effusion 23.9%
amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 18.3%
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 16 more results
amyloid related imaging abnormality-oedema/effusion 27.3%
amyloid related imaging abnormality-microhaemorrhages and haemosiderin deposits 18.2%
infusion related reaction 14.5%
NCT04640077 · Phase 2 · registry result, not featured evidence
amyloid related imaging abnormality-oedema/effusion 25.2% (placebo 0.8%)
fall 14.5% (placebo 16.8%)
superficial siderosis of central nervous system 13.7% (placebo 3.2%)
NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy
amyloid related imaging abnormality-oedema/effusion 26.7% (placebo 0.8%)
dizziness 26.7% (placebo 11.2%)
arthralgia 20% (placebo 8%)
NCT03367403 · Phase 2 · registry result, not featured evidence · combination
40 mg/kg SD
vasogenic cerebral oedema 50% (placebo 0%)
anxiety 25% (placebo 0%)
post lumbar puncture syndrome 25% (placebo 0%)
NCT02624778 · Phase 1 · registry result, not featured evidence
20 mg/kg SD
headache 28.6% (placebo 0%)
vasogenic cerebral oedema 28.6% (placebo 0%)
asthenia 14.3% (placebo 0%)
NCT02624778 · Phase 1 · registry result, not featured evidence
20 mg/kg Q4W
cerebral microhaemorrhage 20% (placebo 0%)
vasogenic cerebral oedema 20% (placebo 0%)
arthralgia 10% (placebo 0%)
NCT02624778 · Phase 1 · registry result, not featured evidence
10 mg/kg SD
back pain 14.3% (placebo 0%)
cellulitis 14.3% (placebo 0%)
cerebral microhaemorrhage 14.3% (placebo 0%)
NCT02624778 · Phase 1 · registry result, not featured evidence
10 mg/kg Q2W
breast pain 25% (placebo 0%)
cerebral microhaemorrhage 20% (placebo 0%)
fatigue 20% (placebo 14.3%)
NCT02624778 · Phase 1 · registry result, not featured evidence
10 mg/kg Q4W
vasogenic cerebral oedema 37.5% (placebo 0%)
anger 25% (placebo 0%)
upper respiratory tract infection 25% (placebo 28.6%)
NCT02624778 · Phase 1 · registry result, not featured evidence
10 mg/kg IV
allergic sinusitis 16.7% (placebo 0%)
bronchitis 16.7% (placebo 0%)
ligament sprain 16.7% (placebo 0%)
NCT01837641 · Phase 1 · registry result, not featured evidence
3 mg/kg IV
infusion related reaction 27.3% (placebo 0%)
fall 18.2% (placebo 0%)
bursitis 9.1% (placebo 0%)
NCT01837641 · Phase 1 · registry result, not featured evidence
3 mg/kg SC
cerebral microhaemorrhage 12.5% (placebo 0%)
fall 12.5% (placebo 0%)
hypothyroidism 12.5% (placebo 0%)
NCT01837641 · Phase 1 · registry result, not featured evidence
1 mg/kg IV
infusion related reaction 22.2% (placebo 0%)
arrhythmia 11.1% (placebo 0%)
confusional state 11.1% (placebo 0%)
NCT01837641 · Phase 1 · registry result, not featured evidence
1 mg/kg IV
nausea 16.7% (placebo 0%)
presyncope 16.7% (placebo 0%)
upper respiratory tract infection 16.7% (placebo 8.3%)
NCT01837641 · Phase 1 · registry result, not featured evidence
0.3 mg/kg IV
cellulitis 14.3% (placebo 0%)
diarrhoea 14.3% (placebo 0%)
dizziness 14.3% (placebo 0%)
NCT01837641 · Phase 1 · registry result, not featured evidence
0.1 mg/kg / 0.3 mg/kg IV
apathy 25% (placebo 0%)
arthralgia 25% (placebo 0%)
chest discomfort 25% (placebo 0%)
NCT01837641 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 17 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Donanemab

Complete Amyloid Clearance 37.9% (n=66) vs 1.6% (n=64) Aducanumab @ 26wk
responder rate · % of participants
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 5 more results
38.5% (n=26) vs 3.8% (n=26) Aducanumab @ 26wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
70% (n=67) vs 24.59% (n=65) Aducanumab @ 52wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
76% (n=26) vs 18.52% (n=27) Aducanumab @ 52wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
76.79% (n=67) vs 43.1% (n=65) Aducanumab @ 78wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
72% (n=26) vs 43.48% (n=27) Aducanumab @ 78wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
Brain Amyloid Change Centiloids -62.104 vs -16.413 Aducanumab Centiloids @ 26wk
absolute change · Centiloids
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 8 more results
-64.076 vs -23.824 Aducanumab Centiloids @ 26wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-80.03 vs -56.06 Aducanumab Centiloids @ 52wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-84.53 vs -57.77 Aducanumab Centiloids @ 52wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-63.987 vs -56.056 Aducanumab Centiloids
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-63.987 vs -56.056 Aducanumab Centiloids
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-84.22 vs -72.18 Aducanumab Centiloids @ 78wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-86.57 vs -72.24 Aducanumab Centiloids @ 78wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-64.347 vs -72.178 Aducanumab Centiloids
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
Brain Amyloid -65.169% (n=66) vs -16.956% (n=64) Aducanumab @ 26wk
percent change · % of baseline
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
show 2 more results
-82.79% (n=67) vs -56.97% (n=65) Aducanumab @ 52wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
-86.29% (n=67) vs -72.84% (n=65) Aducanumab @ 78wk
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3
Time to Complete Amyloid Clearance 11.79 vs 18.66 Aducanumab months
time to event · months
NCT05108922 · Phase 3 · monotherapy · Alzheimer's Disease · phase 3 · converted to months from 359 days as posted
MMSE -0.87 score @ 72wk
absolute change · score
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
ADAS-Cog13 4.63 score @ 72wk
absolute change · score
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
iADRS -10.14 score @ 72wk
absolute change · score
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
ADCS-ADL -6.21 score @ 72wk
absolute change · score
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
CDR-SB 1.87 score @ 72wk
absolute change · score
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
Brain Amyloid Change Centiloids -80.1 Centiloids @ 36wk
absolute change · Centiloids
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
Whole Brain Volume Change Cm3 -27.75 cm @ 72wk
absolute change · cm
No placebo or comparator arm
NCT04640077 · Phase 2 · registry result, not featured evidence
iADRS -6.86 vs -10.06 placebo score @ 76wk
absolute change · score
NCT03367403 · Phase 2 · registry result, not featured evidence · monotherapy

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Donanemab's landscape · SHR-1707's landscape